Core Insights - Achilles Therapeutics has reported interim Phase I/IIa data on clonal neoantigen reactive T cells (cNeT) for treating advanced non-small cell lung cancer (NSCLC) and malignant melanoma, showing improved manufacturing processes and patient outcomes [1][3] Manufacturing Process - The VELOS™ manufacturing process has been enhanced, achieving a median of 172 million cNeT doses across 18 patients, a significant increase from 18 million cNeT in the previous update [2][4] - Ten products delivered over 100 million cNeT, with five exceeding one billion cNeT [2][4] Clinical Trials and Patient Data - The update includes data from 18 patients (12 in CHIRON and 6 in THETIS), with a median of two prior lines of therapy [3][4] - Enhanced host conditioning has been introduced in Cohort C, with initial results showing improved cNeT persistence and engraftment [1][4] - No new objective responses were observed, attributed to limited cNeT persistence with previous conditioning regimens [4] Safety and Tolerability - The tolerability profiles for cNeT remain favorable and comparable to standard TIL therapy, with lymphopenia and neutropenia as the most common adverse events [2][3] - No dose-limiting high-grade toxicities were reported [2][4] Future Directions - The company plans to evaluate cNeT persistence and clinical activity in patients with enhanced host conditioning, with a meaningful data update expected in the second half of 2024 [1][3]
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning